Peritoneal Recurrence of Cecal Cancer with Specific Imaging Findings and Shrinkage after Treatment with Pembrolizumab

Peritoneal Recurrence of Cecal Cancer with Specific Imaging Findings and Shrinkage after Treatment with Pembrolizumab

Pembrolizumab is one of the treatment options for treatment-refractory unresectable advanced or metastatic colorectal cancer with microsatellite instability-high (MSI-H) or deficiencies in DNA mismatch repair (dMMR). Herein, we report a case in which a recurrent cecal cancer lesion showed specific i...

Full description

Bibliographic Details
Main Authors: Tomohiro Takeda, Tatsuya Shonaka, Ryotaro Shimazaki, Yuki Adachi, Masahide Otani, Wakako Matsushita, Chikayoshi Tani, Kimiharu Hasegawa, Yasuo Sumi
Format: Article
Language:English
Published: The Japan Society of Coloproctology 2022-01-01
Series:Journal of the Anus, Rectum and Colon
Subjects:
colorectal cancer
pembrolizumab
msi-h
dmmr
peritoneal recurrence
Online Access:https://www.jstage.jst.go.jp/article/jarc/6/1/6_2021-053/_pdf/-char/en

Internet

https://www.jstage.jst.go.jp/article/jarc/6/1/6_2021-053/_pdf/-char/en

Similar Items